Evaluation of normalization of cerebro-placental ratio as a potential predictor for adverse outcome in SGA fetuses.

What Was Tested

The paper reports a study of Cerebrolysin, published as an observational study.

The primary goal of antenatal care is the early recognition of such conditions to allow treatment and optimization of both maternal and fetal outcomes.

The aim of the Prospective Observational Trial to Optimize Pediatric Health in Intrauterine Growth Restriction study was to evaluate the optimal management of fetuses with an estimated fetal weight <10th centile.

The objective of this secondary analysis was to evaluate if normalizing cerebroplacental ratio predicts adverse perinatal outcome.

Why It Was Studied

Management of pregnancies complicated by intrauterine growth restriction remains one of the greatest challenges in obstetrics.

Frequently, however, clinical evidence of underlying uteroplacental dysfunction may only emerge at a late stage in the disease process.

Who Took Part

The age groups tagged for this paper are adults, women only.

How the Study Was Run

Cerebroplacental ratio was calculated using the pulsatility and resistance indices of the middle cerebral and umbilical artery.

Abnormal cerebroplacental ratio was defined as <1.0.

What Was Measured

Management of pregnancies complicated by intrauterine growth restriction remains one of the greatest challenges in obstetrics.

PubMed files the paper under topics including Cerebral Arteries, Fetal Growth Retardation, Gestational Age, Placenta, Predictive Value of Tests, Prognosis and Ultrasonography, Doppler.

Author keywords: adverse neonatal outcome, brain sparing, brain-sparing effect, cerebroplacental ratio, intrauterine growth restriction and middle cerebral artery Doppler.

What This Means in Plain Language

This is an observational study of Cerebrolysin.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (American journal of obstetrics and gynecology), a journal based in United States.

More context: the Cerebrolysin compound page, all human trials.